Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer

Kim, Eunjung; Jeong, Pildu; Quan, Changyi; Kim, Jiyeon; Bae, Suk‐Chul; Yoon, Seok Jung; Kang, Jeong Woo; Lee, Sang Cheol; Wee, Jae Jun; Kim, Wun-Jae

doi:10.1016/j.urology.2004.08.005

Cited by 103 publications

(73 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these SNPs are reportedly implicated in the risk of various types of cancers such as breast, prostate, bladder cancer and malignant melanoma (16)(17)(18)(19) and associations of the SNPs with plasma and urinary VEGF expression levels were demonstrated (20)(21)(22)(23). Genetic polymorphisms have also shown to affect the risk of cancer and the survival of cancer patients suggesting that polymorphisms as host genetic factors are partially involved in the progression and response to cancer treatments (24).…”

Section: Introductionmentioning

confidence: 99%

Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer

Fukuda

Tsuchiya²,

Narita³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. Vascular endothelial growth factor (VEGF), one of the most potent angiogenic factors, is suggested to play a crucial role in tumor neovascularization and is associated with tumor progression and metastasis in prostate cancer. This study evaluated the significance of the VEGF T-460C polymorphism in the risk and the progression of prostate cancer. In a case-control experiment, 270 patients with prostate cancer and 252 male controls were investigated to assess the association of the VEGF T-460C polymorphism with the risk of prostate cancer. Prostate-specific antigen (PSA) recurrence in 95 patients who underwent radical prostatectomy and survival in 99 patients with metastases at diagnosis were analyzed to evaluate the influence of the polymorphism in cancer progression. The CC and TC genotypes of the polymorphism were associated with significantly higher rates of PSA recurrence after radical prostatectomy than the TT genotype and were independent predictors of PSA recurrence (P=0.011) in a multivariate analysis. In contrast, metastatic prostate cancer patients with the TT genotype showed significantly worse survival as compared to the CC and TC genotypes. In a multivariate analysis, the TT genotype was an independent predictor of cancer-specific survival (P=0.006). The VEGF T-460C polymorphism may have a substantial impact on both PSA recurrence after radical prostatectomy and survival in advanced prostate cancer. The molecular mechanisms of the polymorphism on the differing status in prostate cancer should be elucidated in further studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer

Fukuda

Tsuchiya²,

Narita³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Among these, the VEGF À634G/C, À1154G/A, and À2578C/A polymorphisms have been shown to be associated with an increased VEGF production (11 -13). Recently, VEGF polymorphisms were evaluated in melanoma (14) and bladder (15), lung (16), prostate (17), and breast cancer (18,19) patients. Various studies focused on the prognostic potential of VEGF polymorphisms (15,18,19).…”

mentioning

confidence: 99%

Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

Hefler¹,

Mustea²,

Könsgen³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular permeability, is involved in various steps of ovarian carcinogenesis. Gene polymorphisms within the gene encoding VEGF were shown to be independently associated with an adverse outcome in various malignancies. No data are available for ovarian cancer. Experimental Design: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (−634G/C, −1154G/A, and −2578C/A) known to be associated with an increased VEGF production in 563 Caucasian patients with ovarian cancer from Austria and Germany using pyrosequencing. Results were correlated with clinical data. Results: The three investigated polymorphisms did not correlate with any of the investigated clinicopathologic variables. In univariate and multivariate models, no significant correlations between any polymorphism and patients' overall survival were ascertained. Simultaneous carriage of the three homozygous genotypes (i.e., VEGF −634C/C, VEGF −1154G/G, VEGF −2578C/C) known to be associated with increased VEGF expression in an individual patient, however, was independently associated with a shortened overall survival (hazard ratio, 2.1; 95% confidence interval, 1.1-3.9; P = 0.02). Conclusions: We present the first data on VEGF gene polymorphisms in ovarian cancer. Simultaneous carriage of the three investigated homozygous genotypes was shown to be an independent adverse prognosticator of overall survival.

show abstract

“…The TNF-α 308G/A polymorphism is a G/A polymorphism at nucleotide (nt) -308, and is associated with the development of several urogenital cancers, including prostate cancer (Zabaleta et al, 2008;Moore et al, 2009;Jones et al, 2013), cervical cancer (Singh, 2009;Zuo et al, 2011), bladder cancer (Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005), and renal cell carcinoma (Jang et al, 2001). For example, Jeong et al (2004) studied 113 patients with bladder cancer and 109 healthy subjects and found that the genotype of the 308 nucleotide in the TNF-α promoter had a statistically significant effect on TNF-α production and was related to the bladder tumor grade.…”

Section: Discussionmentioning

confidence: 99%

“…There are 13 studies (Oh et al, 2000;McCarron et al, 2002;Wu, 2004;Jinchao, 2007;Danforth et al, 2008;Sáenz-López et al, 2008;Zabaleta et al, 2008;Kesarwani, 2009;Moore et al, 2009;Wang et al, 2009a;Zhang et al, 2010;Berhane et al, 2012;Jones et al, 2013) focusing on prostate cancer, 19 studies (Jang et al, 2001;Calhoun et al, 2002;Gostout et al, 2003;Stanczuk et al, 2003;Deshpande et al, 2005;Duarte et al, 2005;Govan, 2006;Kohaar et al, 2007;Singh, 2009;Wang et al, 2009b;Ivansson, 2010;Zu, 2010;Wang et al, 2011;Zuo et al, 2011;Badano et al, 2012;Barbisan et al, 2012;Hang and Xu, 2012;Wang et al, 2012;Sousa et al, 2014) on cervical cancer, 6 studies (Tsai et al, 2001;Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005;Nonomura et al, 2006;Ahirwar et al, 2008) on bladder cancer, 1 study (Jang et al, 2001) on renal cell cancer, and 1 study (Wu, 2013) on urothelial carcinoma. Five articles (Stanczuk et al, 2003;…”

Section: Study Characteristicsmentioning

confidence: 99%

Association of tumor necrosis factor-α 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. We integrated all the eligible studies and investigated whether the TNF-α 308G/A polymorphism correlates with urogenital cancer risk. Tumor necrosis factor-α (TNF-α) is a risk factor for some urogenital cancers; however, in prostate and bladder cancers the results are controversial. PubMed, EMBASE, Web of Science, the Cochrane Library, the Chinese Biomedical Literature Database, and the Wanfang Database were searched for all case-control studies on the relationship between the TNF-α 308G/A polymorphism and susceptibility to urogenital cancer between January 1994 and January 2015. The pooled odds ratio with 95% confidence interval was calculated to assess the associations. A total of 16103 Association between TNF-α 308G/A and urogenital cancer risk ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 16102-16112 (2015) 504 articles were found, 39 of which involved 11,613 cases and 12,542 controls that fulfilled the inclusion criteria. Overall, the TNF-α 308G/A polymorphism was significantly associated with the risk of urogenital cancer. In the subgroup analysis for different cancer types, significant associations were found in cervical cancer and urothelial carcinoma, while our metaanalysis indicated that there were no significant associations between the TNF-α 308G/A polymorphism and prostate, bladder, or renal cancers. When stratified by ethnicity, significant associations were observed in Caucasian populations, whereas no significant associations were found in African-Americans, Asians, or mixed populations. Furthermore, carriers of the -308A allele among the hospital-based case-control group were at a high risk of urogenital cancer. Our meta-analysis showed that the TNF-α 308G/A polymorphism was significantly associated with urogenital cancer risk, particularly in the Caucasian and hospital-based populations.

show abstract

Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer

Cited by 103 publications

References 20 publications

Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer

Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer

Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer

Association of tumor necrosis factor-α 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis

Contact Info

Product

Resources

About